Tsien's group classified these channels as 'N, 'T, In the 1960s the research groups of Fleckenstein and Godfraind defined 'calcium antagonists' as agents which blocked the entry of calcium into cells via voltage-dependent calcium channels. In a literature search we found 74 compounds in various stages of clinical or preclinical development classed as 'calcium antagonists'. Since the initial work of Fleckenstein [ l ] and Godfraind et al. [2] , it has become apparent that there are many different types of calcium channel, that there are different binding sites for drugs on the various channels, and that the binding of some of the drugs is highly voltage-dependent, allowing selective interactions with certain states of the channels and selective therapeutic interventions. The application of molecular biology has resulted in the definition of the primary structure of many subtypes of the calcium channel and the first steps are being made to define the structure of the drug receptor sites on the channel proteins.
Diversity of calcium channels
A classification of calcium-selective voltagedependent calcium channels is shown in Table 1 .
Abbreviations used: DHP, dihydropyridine; Kapp, apparent affinity constant; KIJme,,,, membrane partition coefficient; K,, equilibrium constant.
and 'L' [3, 41 and Llinas et al. [S] subsequently has shown that a further distinct subtype of 'P channels exists in cerebellar granule and Purkinje cells. L channels are the channels which are sensitive to dihydropyridines (DHPs) and therefore were the channels in heart and smooth muscle targeted by Fleckenstein and Godfraind from the 1960s. There is a high density of L channels in skeletal muscle and the availability of high-affinity radiolabelled probes allowed L channels to be the first sequenced. They consist of several subunits. The a , subunit (skeletal muscle structure [6, 71; rabbit heart structure [8, 91 , rat aorta and brain structure [lo] ; rabbit lung structure [ll] , Fig. l) , forms the ion-selective pore and voltage sensor, and carries the binding sites for DHPs, phenylalkylamines such as verapamil and benzothiazepines such as diltiazem. The protein has four repeating motifs (termed I-IV) and contains, six putative membrane-spanning regions (termed S 1 -S6; Fig. 2 ), of which the S4 spans are the putative voltage sensor (Fig. 2b) . The cardiac subunit, but not the skeletal subunit, has been expressed in Xenopus oocytes and shown to have many of the properties of the L channel [ 81.
Dysgenic mice (mdghdg), which have a lethal mutation [12] and an abnormal a1 gene, no a , unit in the dystrophic skeletal muscle [13] nor L-type 
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Biochemical Society Transactions coupling. This group went on [16] to express the cardiac a1 subunit in dysgenic myotubules and showed that this isoform of the a , subunit functioned as a 'cardiac-type' voltage sensor and ion pore, even when expressed in skeletal muscle. Chimeric forms of the a, subunit were made to define which part of the molecule was critical for excitation-contraction coupling [ 171. Perez-Reyes et al. [18] expressed the a, subunit in murine L cells which have no other L channels and showed that DHP sites and Ca2+ current were expressed. These experiments conclusively show that the a, subunit is the critical voltage sensor and pore of the channel, and has the receptor sites for the drugs classed as 'calcium antagonists'. An a2 subunit (structure: [7] ) does not act as a channei, but increases calcium current following injection of a 1 mRNA in Xenopus oocytes. The / 3 subunit (structure: [19] ) has been shown to increase the rate of activation and inactivation of the channel and to modify DHP-binding to the a , subunit [20] . A y subunit (222 amino acids, structure [21] ) has thus far only been shown to occur in skeletal muscle; the function is unknown. A 6 subunit may be linked by sulphydryl bonds to the a2 subunit. There appear to be diverse forms of L channels, allowing tissue selectivity and diversity of function. The skeletal muscle Q 1 subunit is smaller (212 kDa) than the cardiac form (242 kDa) and is encoded from a different gene; the skeletal muscle a, subunit may act as a voltage sensor for the sarcoplasmic-reticulum calcium-release channel which is ryanodine sensitive [22] and has several different Volume 20
properties from the cardiac subunit [23] . any, specific blockers of T channels and the lack of high-afinity probes has hindered structural definition. N (neuronal) channels are localized in neuronal tissue, and appear to be important for transmitter release. There may be a wide range of N channels, in that the electrophysiological characteristics of N channels varies between different tissues, but these channels are also coupled to a variety of second messenger systems modifying transmitter release (e.g. G proteins) which may alter function. A range of conotoxins bind to and inhibit N-channel activity, blocking transmitter release. The most commonly studied form ( w ) is but one of a range of conotoxins which may have selectivity for N-channel subtypes. P channels were proposed by Llinas et al. [ 51 on the basis that DHP-and conotoxin-resistant currents in cerebellar Purkinje and granule cells and in squid giant axons, were susceptible to funnel web spider venom; in squid-giant-axon transmitter release was dependent on this channel. These channels may form a larger proportion of calcium channels in the brain than was hitherto supposed [24-261. Recently, Mori et a1 [27] have defined from brain cDNA the primary structure of a calcium channel (€31 protein) with similar pharmacology to the P channel; channel activity was expressed in Xenopus oocytes and was dramatically increased by the co-expression of the a2 and B subunits. Conclusive evidence therefore exists for a range of calcium channels.
Thus, Snutch et al. [28] identified four distinct classes of cDNAs from rat brain (A,B,C,D) with the class C polypeptide being 97% homologous to the heart a 1 subunit. Interestingly, the putative voltagesensor unit (S4) differed between A,B and C,D implying potential differences in electrophysiological properties. Snutch et al. [28] estimated that there are a minimum of eight different calciumchannel transcripts in rat brain.
How different do channels need to be to allow different electrophysiologcal properties and sensitivities to drugs? In potassium channels, MacKinnon & Miller [29] found that changes in only one or two amino acids could markedly change sensitivity to toxins. Changes in the S4 region (Fig. 1) What is the molecular site of action? The high affinity for the inactivated state initially suggested that the site of action might be directly on the voltage sensor. On this basis, Langs et al. [35] using SYBYL modelling techniques speculated that DHPs might dock between ArgS3' and Arg534 in the skeletal muscle S4 helix. However, Regulla et al. [36] irradiated [jHInitrendipine or [3H]azidopine to covalently bind these DHPs to the purified a , complex from skeletal muscle, and digested and sequenced the peptides. Nitrendipine was used because it apparently attaches covalently through the nitro group, whereas azidopine, with a pazidobenzoyl grouping at the end of a CSH,, chain attaches 8.4-14.5 A from the DHP ring. Regulla et al. [36] found that nitrendipine bound predominantly to the cytosolic tail beyond IVS6 between amino acids 1390 and 1437 [6] . This region is highly conserved in all L-type channels from cardiac, skeletal and smooth muscle, which is presumably why DHPs bind with high affinity to all these channels, although skeletal muscle differs in affinity (see [33] ; Fig. 2 ). The sequence with the greatest proportion (54%) of binding was from aal390: DWSILGPHHL. Interestingly, the sequence immediately following, which is also highly conserved, is the putative calcium-binding domain for the channel (EF hand, [37] ; (D) EFKAIWAEY- A highly schematic diagram of these sites is shown in Fig. 2 We believe that, in some situations, not only tissue isoforms of the channel, but also membrane properties play critical roles in the definition of potency, as many of the drugs are highly lipophilic and accumulate in the membrane to a very high degree (see below).
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Functional studies
Determination of the affinity of drugs for ion channels is dependent on the use and voltagedependency of the drug, which is in turn dependent on the binding site. At sodium channels, binding of tetrodotoxin is relatively non-voltage-dependent and the relative affinity of sodium channels is consequently easy to quantify. This contrasts markedly with the interaction of DHPs with L channels. It is now accepted that DHPs have high affinity for the inactivated state of the channel [although this may be modified by the Ca'+ concentration at the calcium-binding region, close to the DHP receptor (see above)], and low affinity for other states (closed, open). Consequently there will be an affinity constant for the high-affinity state, which is the high-affinity constant (usually < nM) observed in binding experiments. The calcium-channel activator, Bay K 8644, has been shown to reduce the rate of deactivation (K-1) of the open state, thus resulting in increased channel opening times in the presence of DHP activator.
In functional experiments the proportion of channels in the high-affinity and low-affinity states will critically modify the apparent affinity of DHPs [30, 311. Bean [30] described that for two states of the channel:
where the apparent affinity constant ( Kapp) in a given experimental situation will depend on the high-affinity constant (Kin,,,) and the low-affinity constant ( KL) and the proportion of channels in the high-affinity state ( 1 -L). A further complication is that if the high-affinity state is available for very short periods of time there may not be time to allow equilibrium. These factors allow apparent tissue selectivity for DHPs whereby the drugs do not have time to block, for example, neuronal L channels with short action potentials, whereas L channels in smooth muscle with membrane potentials of only -50 to -55 mV are much more sensitive. Functional experiments may be set up to explore the high-affinity component:
Thus constant potassium-depolarization with 40 m w K + shifts the above equilibrium far to the right (approx. 70% inactivated channels in some tissues, [ 30]), allowing apparently competitive interactions with the channels, with high-affinity antagonistic effects by DHPs of a similar order of potency to that seen in radioligand-binding experiments [39] . However, the complication caused by affinity for a particular channel state may be the critical factor differentiating drugs from toxins, as toxins frequently show little voltage dependency and will block the activity of a channel under all conditions, whereas agents such as DHPs will be active only when the inactivated state predominates.
A further complication in functional and radioligand-binding studies reflects the highly lipophilic nature of many of the drugs. Mason et al. [47] have shown that uptake of DHPs and of other calcium antagonists into biological membranes may be very high, with accumulation of 3000 (nifedipine) to 19 000 (amlodiphe)-fold. This high concentration in the membrane may be in equilibrium with the receptor site so that the apparent affinity constant (KpP) should also be modified by the membrane partition coefficient K,,,,, to give the true local equilibrium constant, K,, which may be four orders of magnitude lower than the constant calculated from the concentration in the aqueous phase:
K;, = ~~, ,~,~~~1~1 1 1 , 1 1 1
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Such drug-lipid interactions may have marked implications in the interaction of charged and neutral compounds. Valdivia & Coronado [48] demonstrated that increasing the ratio of charged to uncharged phospholipids in the membrane bilayer increases the apparent affinity of charged DHPs by nearly one log order, while uncharged molecules were unaffected. Furthermore the presence of membrane proteins further increased the membrane's accumulation of lipophilic agents, possibly resulting from an ionic interaction in the membrane phase [47] . Some workers [e.g. SO] consider that true Kd values may be inversely proportional to Kp,,,, since partitioning into the plasma membrane depletes active drug available for receptor binding (presumably by an aqueous route). However, for DHP antagonists [49] the membrane approach was three orders of magnitude higher than the aqueous approach for receptor binding. For some calcium antagonists, particularly lipophilic class I11 antagonists [39] , this may be of considerable importance, with binding sites for some agents demonstrated in some cardiac and skeletal membrane preparations but not in others. Thus, we have found the affinity of class 111 antagonists to be different at DHP sites in skeletal muscle and brain preparations and these antagonists have particularly high affinity for [3H]fluspirilene binding, which we consider to be prototypical for this class of agent (Fig. 2) . This class of agents also have selective interactions with 'different means of channel activation, compared with DHPs.
In conclusion, molecular biology studies and revised views on the functional consequences of the interactions of drugs with channels have markedly improved our understanding of drugs previously classed as 'calcium antagonists'.
